Mission Bio, Inc. announced today that it has secured funding from U.S. top ranked angel investment group Life Science Angels in a seed round to commercialize its high throughput single-cell genomics system. Mission Bio is developing a microfluidic, droplet-based platform to enable critical advances in diseases like cancer, where elucidating heterogeneity in cell populations is essential.